173 related articles for article (PubMed ID: 9741643)
21. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.
Wright PF; Ankrah S; Henderson SE; Durbin AP; Speicher J; Whitehead SS; Murphy BR; Pletnev AG
Vaccine; 2008 Feb; 26(7):882-90. PubMed ID: 18207289
[TBL] [Abstract][Full Text] [Related]
22. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity.
Hanley KA; Manlucu LR; Manipon GG; Hanson CT; Whitehead SS; Murphy BR; Blaney JE
Vaccine; 2004 Sep; 22(25-26):3440-8. PubMed ID: 15308370
[TBL] [Abstract][Full Text] [Related]
23. Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.
Hanley KA; Goddard LB; Gilmore LE; Scott TW; Speicher J; Murphy BR; Pletnev AG
Vector Borne Zoonotic Dis; 2005; 5(1):1-10. PubMed ID: 15815144
[TBL] [Abstract][Full Text] [Related]
24. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.
Pletnev AG; Bray M; Huggins J; Lai CJ
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10532-6. PubMed ID: 1438242
[TBL] [Abstract][Full Text] [Related]
25. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
[TBL] [Abstract][Full Text] [Related]
26. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
[TBL] [Abstract][Full Text] [Related]
27. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
28. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
Lai CJ; Monath TP
Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.
Hiramatsu K; Tadano M; Men R; Lai CJ
Virology; 1996 Oct; 224(2):437-45. PubMed ID: 8874504
[TBL] [Abstract][Full Text] [Related]
30. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.
Blaney JE; Johnson DH; Firestone CY; Hanson CT; Murphy BR; Whitehead SS
J Virol; 2001 Oct; 75(20):9731-40. PubMed ID: 11559806
[TBL] [Abstract][Full Text] [Related]
31. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys.
Markoff L; Pang X; Houng Hs HS; Falgout B; Olsen R; Jones E; Polo S
J Virol; 2002 Apr; 76(7):3318-28. PubMed ID: 11884557
[TBL] [Abstract][Full Text] [Related]
32. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.
Raviprakash K; Apt D; Brinkman A; Skinner C; Yang S; Dawes G; Ewing D; Wu SJ; Bass S; Punnonen J; Porter K
Virology; 2006 Sep; 353(1):166-73. PubMed ID: 16814355
[TBL] [Abstract][Full Text] [Related]
33. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
Blaney JE; Sathe NS; Goddard L; Hanson CT; Romero TA; Hanley KA; Murphy BR; Whitehead SS
Vaccine; 2008 Feb; 26(6):817-28. PubMed ID: 18191005
[TBL] [Abstract][Full Text] [Related]
34. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
[TBL] [Abstract][Full Text] [Related]
35. A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates.
Govindarajan D; Guan L; Meschino S; Fridman A; Bagchi A; Pak I; ter Meulen J; Casimiro DR; Bett AJ
PLoS One; 2016; 11(3):e0152209. PubMed ID: 27008550
[TBL] [Abstract][Full Text] [Related]
36. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
37. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
Kraiselburd E; Kessler MJ; Torres-Blasini G
Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
[TBL] [Abstract][Full Text] [Related]
38. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
[TBL] [Abstract][Full Text] [Related]
39. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.
Raja NU; Holman DH; Wang D; Raviprakash K; Juompan LY; Deitz SB; Luo M; Zhang J; Porter KR; Dong JY
Am J Trop Med Hyg; 2007 Apr; 76(4):743-51. PubMed ID: 17426182
[TBL] [Abstract][Full Text] [Related]
40. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
Durbin AP; Karron RA; Sun W; Vaughn DW; Reynolds MJ; Perreault JR; Thumar B; Men R; Lai CJ; Elkins WR; Chanock RM; Murphy BR; Whitehead SS
Am J Trop Med Hyg; 2001 Nov; 65(5):405-13. PubMed ID: 11716091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
